CRISPR interference, almost universally abbreviated as CRISPRi, is the gene-silencing cousin of CRISPR-Cas9. Instead of cutting DNA, CRISPRi uses a catalytically inactive Cas9 protein guided by a single guide RNA to physically block transcription — turning genes down or off without ever introducing a double-strand break. In the decade since its 2013 debut, CRISPRi has become the dominant tool for genome-wide loss-of-function screens and is now powering a new generation of epigenetic medicines from Tune Therapeutics, Chroma Medicine, and Epicrispr Biotechnologies.
If standard CRISPR is a pair of molecular scissors, CRISPRi is a molecular roadblock. That distinction matters more than it sounds — because reversibility, tunability, and the absence of permanent DNA damage are exactly what make CRISPRi the safer bet for many therapeutic indications.
What Is CRISPRi?
CRISPRi was introduced by Lei Stanley Qi, Jonathan Weissman, Wendell Lim, and colleagues in a landmark 2013 Cell paper ("Repurposing CRISPR as an RNA-Guided Platform for Sequence-Specific Control of Gene Expression"). The team mutated the two catalytic residues of Streptococcus pyogenes Cas9 — D10A in the RuvC domain and H840A in the HNH domain — to create a "dead Cas9" (dCas9) that retains DNA-binding activity but cannot cleave.
When dCas9 is targeted to a promoter or early coding region by a guide RNA, it physically blocks RNA polymerase II elongation. In bacteria, this alone is enough for strong knockdown. In human cells, however, dCas9 by itself produces only modest repression. The breakthrough came when Luke Gilbert and colleagues fused dCas9 to a KRAB (Krüppel-associated box) domain in 2013–2014, recruiting the endogenous KAP1/SETDB1 silencing complex and producing potent, durable transcriptional shutdown.
The result is a programmable tool that can silence essentially any gene in the human genome by simply changing a 20-nucleotide guide RNA sequence — and, crucially, the silencing is reversible. Remove dCas9-KRAB and the gene comes back on, unless paired with a heritable methylation writer.
How CRISPRi Works at the Molecular Level
The mechanism unfolds in three layers:
1. Guide RNA targeting. A single guide RNA (sgRNA) directs dCas9-KRAB to a specific genomic locus. CRISPRi is most effective when guides are designed within a window of roughly −50 to +300 base pairs around the transcription start site (TSS). Outside this window, repression drops sharply — a property that makes CRISPRi guide design distinct from cutting-CRISPR design.
2. Steric blockade plus chromatin remodeling. When dCas9-KRAB binds, the steric bulk alone interferes with transcription initiation. The KRAB domain then recruits KAP1 (TRIM28), which scaffolds SETDB1, HP1, and the NuRD complex. SETDB1 deposits H3K9me3 — a repressive histone mark — across the surrounding chromatin, locking the gene into a silent state for as long as dCas9-KRAB is expressed.
3. Reversibility (or not). Standard dCas9-KRAB silencing reverses when the editor is removed. But by fusing dCas9 to additional methyltransferase domains — DNMT3A and DNMT3L — researchers have engineered "epigenetic memory" tools that deposit DNA methylation and produce silencing that persists for months after a single transient delivery. This is the basis of the CRISPRoff platform from the Weissman lab (Nuñez et al., Cell, 2021) and the technology underlying Chroma Medicine and Tune Therapeutics' clinical programs.
Key Papers and Milestones
- Qi et al., 2013 (Cell). The foundational paper introducing dCas9-mediated gene repression in E. coli and human cells.
- Larson et al., 2013 (Nature Methods). A companion methods paper detailing CRISPRi protocols.
- Gilbert et al., 2013 (Cell). Introduces dCas9-KRAB for robust mammalian repression and the parallel CRISPRa system.
- Gilbert et al., 2014 (Cell). "Genome-Scale CRISPR-Mediated Control of Gene Repression and Activation" — the first genome-wide CRISPRi/a screens.
- Horlbeck et al., 2016 (eLife). The hCRISPRi-v2 library, optimizing guide design rules that became the field standard.
- Nuñez et al., 2021 (Cell). CRISPRoff — heritable, mitotically stable epigenetic silencing using a single transient transfection.
- Replogle et al., 2022 (Cell). Perturb-seq at genome scale, mapping the function of every expressed human gene by combining CRISPRi with single-cell RNA-seq.
Applications and Use Cases
Functional genomics screens. CRISPRi has become the workhorse for genome-wide loss-of-function screens, particularly in essential genes where cutting CRISPR produces uninterpretable results. Pooled CRISPRi screens have mapped drug resistance mechanisms, identified cancer dependencies, and dissected immune-cell biology.
Therapeutic gene silencing. This is where CRISPRi is moving fastest. FTX-6058 (Fulcrum Therapeutics) was an oral small-molecule program targeting the CRISPRi-validated EED-PRC2 pathway to reactivate fetal hemoglobin in sickle cell disease — illustrating how CRISPRi screens find drug targets even when the therapy itself is not CRISPR. Tune Therapeutics is advancing Tune-401, a dCas9-based epigenetic editor for chronic hepatitis B, into clinical trials in 2026 — silencing cccDNA without cutting it. Chroma Medicine (now part of nChroma Bio after merging with Nvelop) is developing epigenetic editors for liver diseases and cardiovascular indications. Epicrispr Biotechnologies is targeting facioscapulohumeral muscular dystrophy with a CRISPRi approach to silence the toxic DUX4 gene.
Neurodegeneration. CRISPRi is well suited to silencing toxic gain-of-function alleles in diseases like Huntington's, ALS (C9orf72), and frontotemporal dementia. The reversibility is a feature here — patients can be titrated rather than committed irreversibly.
CRISPRi vs Standard CRISPR vs RNAi
| Feature | CRISPRi (dCas9-KRAB) | CRISPR-Cas9 cutting | RNAi (siRNA/shRNA) |
|---|---|---|---|
| Mechanism | Transcriptional block | DNA double-strand break | mRNA degradation |
| Reversible | Yes (unless DNMT-fused) | No | Yes |
| Off-target profile | Very low | Moderate | Moderate (seed-based) |
| Works on non-coding RNAs | Yes | Sometimes | Limited |
| Effect on essential genes | Tunable knockdown | Lethal indels | Tunable knockdown |
| Genomic damage | None | Indels, large deletions, p53 activation | None |
For a primer on the cutting version, see What Is CRISPR? The Complete Guide.
Connection to the Broader Gene Editing Ecosystem
CRISPRi sits in a family of "CRISPR without cutting" technologies that together represent the field's pivot away from double-strand breaks. Its sibling is CRISPRa, which uses dCas9 fused to activator domains to turn genes on. Both share design principles with base editing and prime editing — all four are part of David Liu's broader vision of gene editing without breaks (see David Liu profile). For background on why avoiding cuts matters, our piece on CRISPR off-target effects explains the safety case. Delivery is the perennial bottleneck — CRISPRi cargo is large (dCas9 plus KRAB plus sgRNA) and is being approached through LNPs, AAV split systems, and emerging cell-penetrating peptide delivery strategies. Pioneer Feng Zhang's lab has also contributed compact CRISPRi orthologs to ease delivery (see Feng Zhang profile).
Current Limitations and Challenges
CRISPRi is not a finished technology. Several limitations matter for clinical translation:
- Delivery payload size. dCas9-KRAB is roughly 4.6 kb of coding sequence — too large for a single AAV. Workarounds include split-intein systems, smaller orthologs (dCasX, dSaCas9), and lipid nanoparticle mRNA delivery.
- Sustained expression requirement. Vanilla dCas9-KRAB silencing requires continuous expression of the editor. CRISPRoff and similar memory tools solve this but introduce DNA methylation that may itself drift over years.
- Promoter dependence. Knockdown efficiency varies dramatically with TSS architecture. Genes with multiple TSSs or weak promoters can be hard to fully silence.
- Immune response to dCas9. Most adults harbor pre-existing immunity to S. pyogenes Cas9 proteins. Engineered variants and orthologs from less common species are being explored.
- Tissue access. Outside liver, eye, and ex vivo cells, getting CRISPRi machinery into the right tissue at the right dose remains hard.
FAQ
Does CRISPRi change the DNA sequence?
No. CRISPRi binds DNA but never cuts or modifies the underlying nucleotide sequence. It only changes which proteins assemble at the locus and how the chromatin is marked.
Is CRISPRi reversible?
Standard dCas9-KRAB is reversible — silencing fades when the editor is removed. CRISPRoff and similar DNMT-fusion variants deposit DNA methylation that can persist through cell divisions for months or longer.
How is CRISPRi different from RNAi?
RNAi degrades mRNA after it has been transcribed; CRISPRi prevents transcription in the first place. CRISPRi is more specific (no seed-based off-targets), works on non-coding RNAs and enhancers, and produces deeper knockdown.
Are any CRISPRi therapies in clinical trials?
Tune Therapeutics' Tune-401 program for chronic hepatitis B is advancing into clinical testing in 2026, and Chroma Medicine and Epicrispr Biotechnologies have programs approaching IND-enabling studies. No CRISPRi therapy is yet FDA-approved.
Can CRISPRi silence multiple genes at once?
Yes. Multiplexed CRISPRi using arrays of guide RNAs has been used to silence dozens of genes simultaneously, which is a major advantage over RNAi.
Why use CRISPRi instead of just knocking out a gene with Cas9?
For essential genes, complete knockout kills cells. For therapeutic targets, permanent DNA damage carries safety risk. CRISPRi gives tunable, reversible control without scarring the genome.
